Reactions 1680, p21 - 2 Dec 2017 Acquired resistance to alectinib during treatment of AKK-positive lung tumour: case report A 51-year-old man had acquired resistance to alectinib treatment of during AKK-positive lung tumour with alectinib [dosage and route not stated]. The man, who had AKK-positive lung tumour, was started on first-line treatment with alectinib. However, he acquired resistance to alectinib in three months. Subsequently, the man was started on ceritinib or crizotinib, which showed only a moderate and temporary effect. Later, he died of unspecified reasons [outcome of reaction not stated]. Author comment: "However, acquired resistance to alectinib is inevitable" "The lung tumors acquired resistance to first-line treatment of alectinib in three months" Makimoto G, et al. A comprehensive analysis of autopsied specimens and patient derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib. Cancer Research 77 (Suppl. 13): abstr. 3164, Jul 2017. Available from: URL: http://doi.org/10.1158/1538-7445.AM2017-3164 [abstract] - Japan 803284842 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera